Venetoclax combined with azacitidine

Venetoclax can be used in combination withAzacitidine, decitabine, or low-dose cytarabineIn adults 75 years of age or older with newly diagnosed acute myeloid leukemia or with comorbidities that preclude the use of intensive induction chemotherapy. Clinical studies of venetoclax showed that combination treatment with azacitidine achieved remission in two-thirds of patients and significantly prolonged median overall survival. This therapy is increasingly used in clinical practice and has established a new standard of care.

Recommended doses and increments of venetoclax depend on the combination, following a dosing schedule that includes 3- or 4-day dose escalations, beginning on Day 1 of Cycle 1 with an oral dose of 100 mg, followed by 200 mg on Day 2 and 400 mg on Day 3. mg, the daily oral dose is 400 mg on day 4 and thereafter; 75 mg/m2 of azacitidine can be administered intravenously or subcutaneously once daily on days 1 to 7 of each 28-day cycle.

The original drug of Venacla is already on the market in China, and can be found in the Category B medical insurance directory. The specification is 100mg*14 tablets and the price per box may be around RMB 5,000. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).